Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 known ✓ | P56524 | 4/20 | 0.43 |
| ▸ | HDAC3 known ✓ | O15379 | 4/20 | 0.42 |
| ▸ | HDAC1 known ✓ | Q13547 | 4/20 | 0.42 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 3/20 | 0.42 |
| ▸ | HDAC2 known ✓ | Q92769 | 3/20 | 0.42 |
| ▸ | HDAC10 known ✓ | Q969S8 | 3/20 | 0.42 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 3/20 | 0.42 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 3/20 | 0.42 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 3/20 | 0.42 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 3/20 | 0.42 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | Q9HBH1 | 1/20 | 0.45 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10768387 | 1.00 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AMITF | |
| Hydrochloric Acid SCHEMBL593062 | 1.00 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AMITF | |
| SCHEMBL701212 | 0.99 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2AMITF | |
| SCHEMBL2936175 | 0.99 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2AMITF | |
| SCHEMBL591280 | 0.99 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2AMITF | |
| SCHEMBL7888177 | 0.90 | PDF (0.45) | NPC1RAB9AMEN1KMT2AMITF | |
| SCHEMBL5576719 | 0.88 | KISS1R (0.46) | NPC1RAB9AMEN1KMT2AMITF | |
| SCHEMBL8002080 | 0.88 | NPC1 (0.42) | NPC1RAB9AMEN1KMT2AMITF | |
| Hydrochloric Acid SCHEMBL5847438 | 0.88 | NPC1 (0.40) | NPC1RAB9AMEN1KMT2AMITF | |
| Hydrochloric Acid SCHEMBL566787 | 0.87 | SSTR3 (0.51) | NPC1RAB9ASSTR3SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564636-B2 | Pnictogen-containing heterocyclic compounds and their use | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240285772-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | COLGATE UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-113908157-B | Application of nicotinamide in preparation of anti-porphyromonas gingivalis medicine | 四川大学 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-113908157-A | Application of nicotinamide in preparation of anti-porphyromonas gingivalis medicine | 四川大学 | 2022-01-11 | — | — | CN | disclosed |
| EP-2506877-B1 | THERAPIES FOR PREVENTING OR SUPPRESSING CLOSTRIDIUM DIFFICILE INFECTION | SEC DEP FOR HEALTH AND SOCIAL CARE (GB) | 2021-08-04 | — | — | EP | disclosed |
| US-20200345032-A1 | Enzymatic-Based Process for the Extraction of Value Added Products from Raw Biomasses | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2020-11-05 | — | — | US | disclosed |
| EP-3614857-A1 | ENZYMATIC-BASED PROCESS FOR THE EXTRACTION OF VALUE ADDED PRODUCTS FROM RAW BIOMASSES | National Research Council of Canada (CA) | 2020-03-04 | — | — | EP | disclosed |
| EP-2054514-A2 | ENZYME SENSORS, METHODS FOR PREPARING AND USING SUCH SENSORS, AND METHODS OF DETECTING PROTEASE ACTIVITY | Georgia State University Research Foundation, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080268497-A1 | Using mixture comprising digestive enzyme and gold particles to prepare tissue for mass spectrum proteomic analysis | CANON KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| WO-2008019123-A2 | ENZYME SENSORS, METHODS FOR PREPARING AND USING SUCH SENSORS, AND METHODS OF DETECTING PROTEASE ACTIVITY | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2006060774-A2 | AGENTS THAT INHIBIT FLAVIVIRUS REPLICATION AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-06-08 | — | — | WO | disclosed |
| US-5185246-A | Using membrane with specific pore size to trap particles and pass seminal plasma | DEUTSCH ALICE (US) | 1993-02-09 | — | — | US | disclosed |
| US-5075335-A | Enzyme inhibitors | EISAI CO., LTD. (JP) | 1991-12-24 | — | — | US | disclosed |
| US-5028526-A | Applying to a membrane which allows plasma to pass through and retains the particles | Deutsch, Alice (US) | 1991-07-02 | — | — | US | disclosed |
| US-4948808-A | ENZYME INHIBITORS | EISAI CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
| EP-0229370-B1 | GUANIDINOBENZOIC ESTER DERIVATIVE, A PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Eisai Co., Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
| US-4801603-A | ENZYME INHIBITORS, TREATMENT OF PANCREATITIS, HEMORRHAGE, THROMBOSIS | EISAI CO., LTD. (JP) | 1989-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564636-B2 | Pnictogen-containing heterocyclic compounds and their use | CBR1, PNPO, NOX3 | HDAC4 3886/4885HDAC3 1125/4885HDAC1 2890/4885 |
| US-20240285772-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | PYGL, UGT2B7, CYP2E1 | HDAC4 3132/4885HDAC3 1162/4885HDAC1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.